Skip to content

A clinical trial to improve the immune status of treated head and neck cancer patients and to prevent recurrence.

The role of indigenous medicinal products in reducing the relapse rate of head and neck cancers a randomized controlled pilot study. - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/05/002667
Enrollment
100
Registered
2012-05-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Head and neck cancers treated with radical radiotherapy and are in complete remission

Interventions

Intervention1: Varanadi Ghritha: VaranadiGhritha is a polyherbal compound used in Ayurvedic system of medicine since several years for the management of ailments of the head and neck region. It is ind

Sponsors

Kerala State Council for Science Technology and Environment
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects aged 25 â?? 70 years with head and neck cancers, in complete remission on two consecutive visits after the completion of radical radiotherapy ± chemotherapy will be eligible

Exclusion criteria

Exclusion criteria: Patients with any one or more of the following condition, •Hypertension and Diabetes •Performance status 3 or more •Serum cholesterol above 250mg% •History of liver disease (hepatitis, cirrhosis liver) •History of ischemic heart disease including angina •Kidney disease (urine albumin +, blood urea above 50mg%) •Mental illness •Pregnant women •Unwillingness to participate in the study

Design outcomes

Primary

MeasureTime frame
a)Loco - regional recurrence b)Second primary tumours Timepoint: Locoregional recurrence and occurrence of second primary tumours after 2 years of recruitment.

Secondary

MeasureTime frame
Changes in the level of markers of immune systemTimepoint: Change in the level of immune markers from baseline and after 1 year of administration of compound

Countries

India

Contacts

Public ContactDr Divya Ravindran

Regional Cancer Centre Thiruvananthapuram

divyarcc@gmail.com04712522239

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026